European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact
Guidelines

Non-muscle-invasive Bladder Cancer

Want to read the guideline in your own time? Download the PDF

Download full guideline

Looking for a quick overview? Check the pocket guidelines.

Download pocket guidelines
Full text guidelineSummary of ChangesPublications & AppendicesPanelRelated content
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
2025
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • No elements found. Consider changing the search query.
  • List is empty.

For the 2025 Non-muscle-invasive Bladder Cancer Guidelines new and relevant evidence was identified, collated and appraised through a structured assessment of the literature for all sections of the Guidelines. This resulted in the inclusion of 36 updated studies across the Guidelines. Key changes include:

  • The addition of a new recommendations to section 5.9 related to the timing of MRI for local staging of bladder cancer. In addition, in section 5.9 the recommendation on the use of flexible cystoscope in men and women has also been updated.
  • A new section, section 6.3, on histological subtypes has been added to the guideline including Table 6.1 which outlines subtype prognostic factors and risk of progression.
  • Section 7.9.2 “Recurrence during or after intravesical BCG therapy” has been restructured to more clearly present the definitions of BCG failure and the treatment options for BCG-unresponsive tumours.
  • Adaption of the recommendation on active surveillance in section 7.10.
  • Significant adaption and expansion of section 8.1.5.4 “Urinary molecular markers” including the inclusion of a new table on the performance of multiplex urine markers in the surveillance setting.
  • Addition of a new section, section 10, on pragmatic de-intensification strategy for NMIBC.
About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer